Key result
Amlodipine/atorvastatin single-pill therapy enabled 57.7% of patients with concomitant hypertension and dyslipidemia to achieve both blood pressure and LDL cholesterol goals at 14 weeks.
Why the study?
Does amlodipine/atorvastatin single-pill therapy improve achievement of blood pressure and lipid goals in patients with concomitant hypertension and dyslipidemia?
Does amlodipine/atorvastatin single-pill therapy improve achievement of blood pressure and lipid goals in patients with concomitant hypertension and dyslipidemia?
Single-pill amlodipine/atorvastatin therapy effectively helps over half of patients with concomitant hypertension and dyslipidemia achieve both blood pressure and lipid goals.
May support single-pill amlodipine/atorvastatin in comorbid hypertension and dyslipidemia; extends observational data but leaves open need for RCTs.
The Gemini Study was a 14-week, open-label, non-comparative, office-based, multicenter trial to evaluate single-pill therapy in the treatment of concomitant hypertension and dyslipidemia. In addition to recommending lifestyle modifications, eight dosage strengths of amlodipine/atorvastatin single pill (5/10, 5/20, 5/40, 5/80, 10/10, 10/20, 10/40, and 10/80 mg) were electively titrated to improve blood pressure and lipid control. A total of 1220 patients with uncontrolled hypertension at baseline received study medication. At baseline, mean blood pressure was 146.6/87.9 mm Hg and mean low-density lipoprotein cholesterol concentration was 152.9 mg/dL. At study end, 57.7% of patients had achieved both their blood pressure and low-density lipoprotein cholesterol goals (51.9% of patients with uncontrolled low-density lipoprotein cholesterol at baseline). The mean dose of study medication at end point was amlodipine component 7.1 mg and atorvastatin component 26.2 mg. Fifty-eight patients (4.8%) discontinued therapy due to adverse events. Single-pill therapy is effective in reducing both blood pressure and lipid levels and in helping patients achieve goals for both hypertension and dyslipidemia.
No takes yet. Share an insight, caveat, or question.
Blank et al. (2005) studied Concomitant hypertension and dyslipidemia (n=1,220). Amlodipine/atorvastatin single pill was evaluated on Achievement of both blood pressure and low-density lipoprotein cholesterol goals. Amlodipine/atorvastatin single-pill therapy enabled 57.7% of patients with concomitant hypertension and dyslipidemia to achieve both blood pressure and LDL cholesterol goals at 14 weeks.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: